Home/Filings/4/0001209191-19-053664

4//SEC Filing

ARCH Venture Partners IX, LLC 4

Accession 0001209191-19-053664

CIK 0001706431other

View on SEC.gov Company Profile

Filed

Oct 17, 8:00 PM ET

Accepted

Oct 18, 7:54 PM ET

Size

30.0 KB

Accession

0001209191-19-053664

Insider Transaction Report

Form 4

Period: 2019-10-16

Vir Biotechnology, Inc.VIR

ARCH Venture Fund IX, L.P.

10% Owner

Transactions

Conversion
Series A-1 Convertible Preferred Stock
2019-10-16−11,111,110→ 0 total(indirect: See footnote)
→ Common Stock (11,111,110 underlying)
Conversion
Series A-1 Convertible Preferred Stock
2019-10-16−13,333,332→ 0 total(indirect: See footnote)
→ Common Stock (13,333,332 underlying)
Conversion
Series B Convertible Preferred Stock
2019-10-16−555,555→ 0 total(indirect: See footnote)
→ Common Stock (555,555 underlying)
Conversion
Series B Convertible Preferred Stock
2019-10-16−2,222,222→ 0 total(indirect: See footnote)
→ Common Stock (2,222,222 underlying)
Conversion
Common Stock
2019-10-16+15,555,554→ 15,555,554 total(indirect: See footnote)
Conversion
Common Stock
2019-10-16+11,666,665→ 12,111,109 total(indirect: See footnote)
Purchase
Common Stock
2019-10-16$20.00/sh+1,000,000$20,000,000→ 1,000,000 total(indirect: See footnote)

ARCH Venture Partners IX, L.P.

10% Owner

Transactions

Conversion
Common Stock
2019-10-16+15,555,554→ 15,555,554 total(indirect: See footnote)
Conversion
Series A-1 Convertible Preferred Stock
2019-10-16−13,333,332→ 0 total(indirect: See footnote)
→ Common Stock (13,333,332 underlying)
Conversion
Series B Convertible Preferred Stock
2019-10-16−555,555→ 0 total(indirect: See footnote)
→ Common Stock (555,555 underlying)
Conversion
Series B Convertible Preferred Stock
2019-10-16−2,222,222→ 0 total(indirect: See footnote)
→ Common Stock (2,222,222 underlying)
Conversion
Common Stock
2019-10-16+11,666,665→ 12,111,109 total(indirect: See footnote)
Purchase
Common Stock
2019-10-16$20.00/sh+1,000,000$20,000,000→ 1,000,000 total(indirect: See footnote)
Conversion
Series A-1 Convertible Preferred Stock
2019-10-16−11,111,110→ 0 total(indirect: See footnote)
→ Common Stock (11,111,110 underlying)

ARCH Venture Partners IX, LLC

10% Owner

Transactions

Conversion
Common Stock
2019-10-16+11,666,665→ 12,111,109 total(indirect: See footnote)
Conversion
Common Stock
2019-10-16+15,555,554→ 15,555,554 total(indirect: See footnote)
Purchase
Common Stock
2019-10-16$20.00/sh+1,000,000$20,000,000→ 1,000,000 total(indirect: See footnote)
Conversion
Series A-1 Convertible Preferred Stock
2019-10-16−11,111,110→ 0 total(indirect: See footnote)
→ Common Stock (11,111,110 underlying)
Conversion
Series B Convertible Preferred Stock
2019-10-16−555,555→ 0 total(indirect: See footnote)
→ Common Stock (555,555 underlying)
Conversion
Series A-1 Convertible Preferred Stock
2019-10-16−13,333,332→ 0 total(indirect: See footnote)
→ Common Stock (13,333,332 underlying)
Conversion
Series B Convertible Preferred Stock
2019-10-16−2,222,222→ 0 total(indirect: See footnote)
→ Common Stock (2,222,222 underlying)

ARCH Venture Fund IX Overage, L.P.

10% Owner

Transactions

Conversion
Common Stock
2019-10-16+15,555,554→ 15,555,554 total(indirect: See footnote)
Conversion
Series A-1 Convertible Preferred Stock
2019-10-16−11,111,110→ 0 total(indirect: See footnote)
→ Common Stock (11,111,110 underlying)
Conversion
Series A-1 Convertible Preferred Stock
2019-10-16−13,333,332→ 0 total(indirect: See footnote)
→ Common Stock (13,333,332 underlying)
Conversion
Series B Convertible Preferred Stock
2019-10-16−555,555→ 0 total(indirect: See footnote)
→ Common Stock (555,555 underlying)
Conversion
Common Stock
2019-10-16+11,666,665→ 12,111,109 total(indirect: See footnote)
Purchase
Common Stock
2019-10-16$20.00/sh+1,000,000$20,000,000→ 1,000,000 total(indirect: See footnote)
Conversion
Series B Convertible Preferred Stock
2019-10-16−2,222,222→ 0 total(indirect: See footnote)
→ Common Stock (2,222,222 underlying)

CRANDELL KEITH

10% Owner

Transactions

Conversion
Common Stock
2019-10-16+11,666,665→ 12,111,109 total(indirect: See footnote)
Purchase
Common Stock
2019-10-16$20.00/sh+1,000,000$20,000,000→ 1,000,000 total(indirect: See footnote)
Conversion
Series A-1 Convertible Preferred Stock
2019-10-16−13,333,332→ 0 total(indirect: See footnote)
→ Common Stock (13,333,332 underlying)
Conversion
Series B Convertible Preferred Stock
2019-10-16−555,555→ 0 total(indirect: See footnote)
→ Common Stock (555,555 underlying)
Conversion
Series B Convertible Preferred Stock
2019-10-16−2,222,222→ 0 total(indirect: See footnote)
→ Common Stock (2,222,222 underlying)
Conversion
Series A-1 Convertible Preferred Stock
2019-10-16−11,111,110→ 0 total(indirect: See footnote)
→ Common Stock (11,111,110 underlying)
Conversion
Common Stock
2019-10-16+15,555,554→ 15,555,554 total(indirect: See footnote)

ARCH Venture Partners IX Overage, L.P.

10% Owner

Transactions

Conversion
Common Stock
2019-10-16+15,555,554→ 15,555,554 total(indirect: See footnote)
Purchase
Common Stock
2019-10-16$20.00/sh+1,000,000$20,000,000→ 1,000,000 total(indirect: See footnote)
Conversion
Series A-1 Convertible Preferred Stock
2019-10-16−13,333,332→ 0 total(indirect: See footnote)
→ Common Stock (13,333,332 underlying)
Conversion
Series B Convertible Preferred Stock
2019-10-16−555,555→ 0 total(indirect: See footnote)
→ Common Stock (555,555 underlying)
Conversion
Series A-1 Convertible Preferred Stock
2019-10-16−11,111,110→ 0 total(indirect: See footnote)
→ Common Stock (11,111,110 underlying)
Conversion
Series B Convertible Preferred Stock
2019-10-16−2,222,222→ 0 total(indirect: See footnote)
→ Common Stock (2,222,222 underlying)
Conversion
Common Stock
2019-10-16+11,666,665→ 12,111,109 total(indirect: See footnote)

BYBEE CLINTON

10% Owner

Transactions

Conversion
Series B Convertible Preferred Stock
2019-10-16−2,222,222→ 0 total(indirect: See footnote)
→ Common Stock (2,222,222 underlying)
Purchase
Common Stock
2019-10-16$20.00/sh+1,000,000$20,000,000→ 1,000,000 total(indirect: See footnote)
Conversion
Series A-1 Convertible Preferred Stock
2019-10-16−11,111,110→ 0 total(indirect: See footnote)
→ Common Stock (11,111,110 underlying)
Conversion
Series B Convertible Preferred Stock
2019-10-16−555,555→ 0 total(indirect: See footnote)
→ Common Stock (555,555 underlying)
Conversion
Common Stock
2019-10-16+11,666,665→ 12,111,109 total(indirect: See footnote)
Conversion
Series A-1 Convertible Preferred Stock
2019-10-16−13,333,332→ 0 total(indirect: See footnote)
→ Common Stock (13,333,332 underlying)
Conversion
Common Stock
2019-10-16+15,555,554→ 15,555,554 total(indirect: See footnote)

Footnotes (4)

[F1]Each share of the Issuer's Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
[F2]These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell, Clinton Bybee and Robert Nelsen (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP,GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
[F3]These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
[F4]These shares are directly held by GPLLC, and each of the ARCH Managing Directors may be deemed to beneficially own the shares held by GPLLC. Each of the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Each of ARCH IX and ARCH Overage has a pecuniary interest in the shares held by GPLLC.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Vir Biotechnology, Inc.

CIK 0001706431

→

Entity typeother

IncorporatedDE

Related Parties

filerCIK 0001723174

Filing Metadata

Form type: 4
Filed: Oct 17, 8:00 PM ET
Accepted: Oct 18, 7:54 PM ET
Size: 30.0 KB

View on SEC.gov